Breaking News

Bayer Drops Out in the Race for Schiff

November 20, 2012

According to published reports, Bayer AG has ceased its pursuit of Schiff Nutrition International Inc., ending speculation that the deal was poised to become the industry’s most expensive acquisition.

Late last month German drugmaker Bayer announced its intent to buy Schiff for $34 a share, or about $1.1 billion including net debt, according to Bloomberg. The situation grew interesting when Reckitt Benckiser Group Plc made a surprise offer of $42 a share, or about $1.4 billion.

In a filing with the U.S. Securities and Exchange Commission Bayer said that a competitive bidding process “would result in a price outside Bayer’s set financial criteria.”

blog comments powered by Disqus
  • Solid Dosage Manufacturing Trends

    Solid Dosage Manufacturing Trends

    Tim Wright, Editor, Contract Pharma ||March 2, 2015
    Big Pharma continues to unload in-house manufacturing, partnering with contract service providers that can meet their cGMP needs.

  • Addressing the Obesity Epidemic

    Addressing the Obesity Epidemic

    David Foreman, RPh, ND, The Herbal Pharmacist||March 2, 2015
    Solutions and supplements to help the needs of an overfed, undernourished society.

  • Cannabis Conundrum

    Cannabis Conundrum

    Alan Richman, Contributing Writer ||March 2, 2015
    Reaction is mixed on whether there is an appropriate role for marijuana in the natural products industry.